01963nas a2200289   4500000000100000008004100001653002000042653002500062653001600087653002500103653001200128100001500140700001500155700001400170700001300184700001700197700001700214700002200231700001300253700001300266245009900279856007300378300001200451490000700463520118900470022001401659       2016                            d10aSerologic Tests10aRecombinant Proteins10aGlycolipids10aMycobacterium leprae10aleprosy1 aFabri ACOC1 aCarvalho A1 aVieira NF1 aBueno IC1 aRodrigues RN1 aMonteiro TBM1 aCorrea-Oliveira R1 aDuthie M1 aLana FCF00aIntegrative literature review of the reported uses of serological tests in leprosy management.  uhttp://www.scielo.br/pdf/rsbmt/v49n2/1678-9849-rsbmt-49-02-00158.pdf  a158-1640 v493 a<p>An integrative literature review was conducted to synthesize available publications regarding the potential use of serological tests in leprosy programs. We searched the databases Literatura Latino-Americana e do Caribe em Ciências da Saúde, Índice Bibliográfico Espanhol em Ciências da Saúde, Acervo da Biblioteca da Organização Pan-Americana da Saúde, Medical Literature Analysis and Retrieval System Online, Hanseníase, National Library of Medicine, Scopus, Ovid, Cinahl, and Web of Science for articles investigating the use of serological tests for antibodies against phenolic glycolipid-I (PGL-I), ML0405, ML2331, leprosy IDRI diagnostic-1 (LID-1), and natural disaccharide octyl-leprosy IDRI diagnostic-1 (NDO-LID). From an initial pool of 3.514 articles, 40 full-length articles fulfilled our inclusion criteria. Based on these papers, we concluded that these antibodies can be used to assist in diagnosing leprosy, detecting neuritis, monitoring therapeutic efficacy, and monitoring household contacts or at-risk populations in leprosy-endemic areas. Thus, available data suggest that serological tests could contribute substantially to leprosy management.</p>
  a1678-9849